(155 days)
The SonoTip Pro and Pro Flex - TBNA Needle System is intended for Ultrasonically Guided Fine Needle Aspiration, (FNA) of submucosal and extraluminal lesions of the Tracheobronchial Tree and Gastrointestinal Tract, (e.g., lymph nodes, abnormal tissue in the mediastinum).
The SonoTip Pro and Pro Flex EBUS-TBNA Needle System is a complete onepiece needle system for Fine Needle Aspiration and is a disposable instrument intended for single patient use only. The SonoTip Pro Flex EBUS-TBNA Needle System is coupled to the working channel of a legally marketed ultrasound endoscope. The needle is then ultrasonically guided and imbedded into the desired target lesion for aspiration of the required biopsy sample. A 2-way stop-cock valve and self-locking aspiration syringe are supplied as procedural aids to provide suction to through the needle lumen and assist in sample acquisition.
Here's an analysis of the provided text regarding the acceptance criteria and study for the SonoTip Pro and Pro Flex EBUS-TBNA Needle System:
1. Table of Acceptance Criteria and Reported Device Performance
| Acceptance Criteria | Reported Device Performance |
|---|---|
| Safety | Demonstrated to be "as safe" as the currently cleared predicate device (SonoTip II EBUS-TBNA Needle System, K091257). |
| Effectiveness | Demonstrated to be "as effective" as the currently cleared predicate device (SonoTip II EBUS-TBNA Needle System, K091257). |
| Performance Requirements | Meets the "same performance requirements" as the predicate device. |
| Intended Use | Has the "same intended use" as the predicate device (Ultrasonically Guided Fine Needle Aspiration (FNA) of submucosal and extraluminal lesions of the Tracheobronchial Tree and Gastrointestinal Tract). |
| Diagnostic/Therapeutic Effect | Has the "same diagnostic/therapeutic effect" as the predicate device. |
| Method of Introduction/Use | Has the "same method of introduction/use" as the predicate device. |
| Technical Characteristics | Possesses "same technical characteristics" as the predicate device, with identified improvements (Nitinol needle material to reduce deformation). |
| General Range of Descriptive Features | Possesses the "same general range of descriptive features" as the predicate device. |
2. Sample Size Used for the Test Set and Data Provenance
The document explicitly states that "Design verification data and biocompatibility testing has demonstrated..." but does not provide details on the sample size used for any specific test set, nor does it specify the data provenance (e.g., country of origin, retrospective or prospective). This information refers to non-clinical testing.
3. Number of Experts Used to Establish the Ground Truth for the Test Set and Qualifications of Those Experts
There is no mention of experts or clinicians used to establish ground truth in the provided text. The evaluation is based on non-clinical data and comparison to a predicate device.
4. Adjudication Method for the Test Set
Since there is no mention of human expert evaluation or a test set involving human judgment, there is no adjudication method described in the document.
5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance
No MRMC study was performed or is mentioned in the document. The device is a biopsy needle system, not an AI-powered diagnostic tool, so such a study would not be relevant.
6. If a Standalone (i.e. algorithm only without human-in-the-loop performance) was done
The device is a physical biopsy needle. No standalone algorithm performance study was performed or is relevant to this type of medical device.
7. The Type of Ground Truth Used
For the non-clinical performance data, the "ground truth" seems to be derived from engineering design verification data and biocompatibility testing results, which likely adhere to established industry standards and internal specifications, allowing for direct comparison to the predicate device's performance.
8. The Sample Size for the Training Set
Since this is a physical medical device and not an AI/software product, there is no concept of a "training set" in the context of the provided information.
9. How the Ground Truth for the Training Set was Established
As there is no training set mentioned, this question is not applicable. The device's performance is established through non-clinical testing and comparison to a predicate device, as described in point 7.
{0}------------------------------------------------
MAY 1 5 2014
510(k) SUMMARY
Date of Preparation: 11/ 8/ 2013
- A. Submitter Information:
Submitter's Name: Medi-Globe Corporation
Submitter's Address: 110 West Orion Street #136 Tempe, Arizona 85283
Contact Person: Scott Karler
Contact Person's Telephone Number: (480) 897-2772 ext. 208
Contact Person's FAX Number: (480) 897-2878
Contact Person's Email Address: skarler(@mediglobe.com
- B. Proposed Device Information
- . Trade Name: SonoTip Pro and Pro Flex EBUS-TBNA Needle System
- Common Name: Biopsy Needle Kit .
- Classification Name: Gastroenterology-Urology Biopsy Instrument 21 . CFR876,1075
- Product Code: FCG .
- C. Predicate Device:
- Trade Name: SonoTip II EBUS-TBNA Needle System .
- Manufacturer: Medi-Globe, GmbH .
- . Clearance Number: K091257
- Common Name: Biopsy Needle Kit .
- Classification Name: Gastroenterology-Urology Biopsy Instrument 21 . CFR876.1075
- Product Code: FCG .
{1}------------------------------------------------
Device Description: D.
The SonoTip Pro and Pro Flex EBUS-TBNA Needle System is a complete onepiece needle system for Fine Needle Aspiration and is a disposable instrument intended for single patient use only. The SonoTip Pro Flex EBUS-TBNA Needle System is coupled to the working channel of a legally marketed ultrasound endoscope. The needle is then ultrasonically guided and imbedded into the desired target lesion for aspiration of the required biopsy sample. A 2-way stop-cock valve and self-locking aspiration syringe are supplied as procedural aids to provide suction to through the needle lumen and assist in sample acquisition.
E. Intended Use:
Indications for Use: The SonoTip Pro and Pro Flex – TBNA Needle System is intended for Ultrasonically Guided Fine Needle Aspiration, (FNA) of submucosal and extraluminal lesions of the Tracheobronchial Tree and Gastrointestinal Tract, (e.g., lymph nodes, abnormal tissue in the mediastinum),
F. Technological Characteristics Summary:
The SonoTip Pro and Pro Flex EBUS-TBNA Needle System is identical when compared to Medi-Globe's own currently cleared device. SonoTip II, (K091257) utilizing endoscopic ultrasound technology which, when used with an ultrasound endoscope, allows the user to ultrasonically guide the biopsy needle to its intended target within or adjacent to the Tracheobronchial Tree or Gastrointestinal Tract. The proposed device is available with a new needle material composed of Nitinol, or with a stainless steel needle as is featured in the currently cleared device models. The Nitinol needle reduces deformation as the needle passes through the distal end of the working channel of some ultrasound endoscopes. In addition, the memory properties of Nitinol reduce deformation of the needle and help to retain the original linear alignment of the needle throughout the procedure.
Non-Clinical Performance Data: ்.
{2}------------------------------------------------
Design verification data and biocompatibility testing has demonstrated that the proposed SonoTip Pro and Pro Flex EBUS-TBNA Needle System meets the same performance requirements and is as safe and effective as Medi-Globe's own currently cleared device, (K091257).
Conclusions of Non-Clinical Performance Data: H.
Medi-Globe Corporation has demonstrated that the proposed SonoTip Pro and Pro Flex EBUS-TBNA Needle System meets the same performance requirements and is as safe and effective as Medi-Globe's own currently cleared predicate device, (SonoTip II EBUS-TBNA Needle System, K091257). The SonoTip Pro and Pro Flex EBUS-TBNA Needle System is considered to have the same intended use, diagnostic/therapeutic effect, method of introduction/use, technical characteristics and general range of descriptive features as the predicate Medi-Globe SonoTip II EBUS-TBNA Needle System (K091257).
{3}------------------------------------------------
Image /page/3/Picture/0 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized graphic of an eagle with three tail feathers, representing the department's mission to protect the health of all Americans and provide essential human services. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular fashion around the graphic.
Public Health Service
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
May 15, 2014
Medi-Globe Corporation Scott Karler Regulatory Affairs Coordinator 110 West Orion Street, Suite # 136 Tempe, AZ 85283
Re: K133763
Trade/Device Name: SonoTip Pro and Pro Flex EBUS-TBNA Needle System Regulation Number: 21 CFR§ 876.1075 Regulation Name: Gastroenterology-urology biopsy instrument Regulatory Class: II Product Code: FCG Dated: April 16, 2014 Received: April 21, 2014
Dear Scott Karler,
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies.
{4}------------------------------------------------
Page 2 - Scott Karler
You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOfTices/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/Reportal/roblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely yours,
Herbert
for
Benjamin R. Fisher, Ph.D. Director Division of Reproductive, Gastro-Renal, and Urological Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{5}------------------------------------------------
Indications for Use
510(k) Number (if known): K133763
Device Name: SonoTip Pro and Pro Flex EBUS-TBNA Needle System
Indications for Use: The SonoTip Pro and Pro Flex - TBNA Needle System is intended for Ultrasonically Guided Fine Needle Aspiration, (FNA) of submucosal and extraluminal lesions of the Tracheobronchial Tree and Gastrointestinal Tract, (e.g., lymph nodes, abnormal tissue in the mediastinum).
V Prescription Use (Part 21 CFR 801 Subpart D)
AND/OR
Over-The-Counter Use (21 CFR 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Herbert F 2014.05.15
Page 1
lof l
§ 876.1075 Gastroenterology-urology biopsy instrument.
(a)
Identification. A gastroenterology-urology biopsy instrument is a device used to remove, by cutting or aspiration, a specimen of tissue for microscopic examination. This generic type of device includes the biopsy punch, gastrointestinal mechanical biopsy instrument, suction biopsy instrument, gastro-urology biopsy needle and needle set, and nonelectric biopsy forceps. This section does not apply to biopsy instruments that have specialized uses in other medical specialty areas and that are covered by classification regulations in other parts of the device classification regulations.(b)
Classification. (1) Class II (performance standards).(2) Class I for the biopsy forceps cover and the non-electric biopsy forceps. The devices subject to this paragraph (b)(2) are exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 876.9.